Seaport Therapeutics, Inc.

Filing Date

May 6, 2026

Transaction Date

May 4, 2026

Accession Number

0000950142-26-001309

Form Type

3

Footnotes

1. (F1)Reflects 6,101,582 shares of Common Stock held by General Atlantic (SP), L.P., or General Atlantic SP, including 3,351,582 shares of Common Stock issuable upon conversion of Series B preferred stock. The limited partners that share beneficial ownership of the shares held by General Atlantic SP, or the GA Funds, are General Atlantic Partners 100, L.P., or GAP 100, General Atlantic Partners (Lux), SCSp, or GAP Lux, GAP Coinvestments III, LLC, or GAPCO III, GAP Coinvestments IV, LLC, or GAPCO IV, GAP Coinvestments V, LLC, or GAPCO V, and GAP Coinvestments CDA, L.P., or GAPCO CDA. The general partner of GAP 100 is General Atlantic GenPar, L.P., (Cont'd in FN2)
2. (F2)(Cont'd from FN1) or GA GenPar. General Atlantic, L.P., or GA LP, which is controlled by the Partnership Committee of GASC MGP, LLC (the "Partnership Committee"), is the managing member of GAPCO III, GAPCO IV and GAPCO V, the general partner of GAPCO CDA and GA GenPar, and the sole member of General Atlantic (SPV) GP, LLC, or GA SPV. The general partner of General Atlantic SP is GA SPV. The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, or GA GenPar Lux, and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a r.l., or GA Lux. The sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., or GenPar Bermuda. GAP (Bermuda) L.P., or GAP Bermuda, which is ultimately controlled by the Partnership Committee, is the general partner of GenPar Bermuda. (Cont'd in FN3)
3. (F3)(Cont'd from FN2) There are six members of the Partnership Committee. Each of the members of the Partnership Committee disclaims ownership of the shares except to the extent that he or she has a pecuniary interest therein.